Claims

[Claim 1]

Use of 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof for the manufacture of an agent for treating heart failure and/or relieving a symptom.

[Claim 2]

The use according to claim 1, wherein the heart failure is acute heart failure or chronic heart failure.

[Claim 3]

The use according to claim 1, wherein the heart failure is diastolic heart failure.

[Claim 4]

The use according to any one of claims 1 to 3, wherein the symptom is congestion, dyspnea, shortness of breath, malaise, decrease in urine volume, limb edema and/or hepatomegaly.

[Claim 5]

Use of 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof for the manufacture of an agent for treating heart failure, which changes Peak positive dP/dt and Peak negative dP/dt of a mammal having a pathological condition of heart failure, wherein the change ratio of the Peak negative dP/dt calculated from the values before and after the administration of the agent is larger than the change ratio of the Peak positive dP/dt.

[Claim 6]

The use according to claim 5, which is a compound for treating diastolic heart failure and/or relieving a symptom.

[Claim 7]

Use of 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, a salt thereof, a solvate

Claims

[Claim 1]

Use of 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof for the manufacture of an agent for treating heart failure and/or relieving a symptom.

[Claim 2]

The use according to claim 1, wherein the heart failure is acute heart failure or chronic heart failure.

[Claim 3]

The use according to claim 1, wherein the heart failure is diastolic heart failure.

[Claim 4]

The use according to any one of claims 1 to 3, wherein the symptom is congestion, dyspnea, shortness of breath, malaise, decrease in urine volume, limb edema and/or hepatomegaly.

[Claim 5]

Use of 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof for the manufacture of an agent for treating heart failure, which changes Peak positive dP/dt and Peak negative dP/dt of a mammal having a pathological condition of heart failure, wherein the change ratio of the Peak negative dP/dt calculated from the values before and after the administration of the agent is larger than the change ratio of the Peak positive dP/dt.

[Claim 6]

The use according to claim 5, which is use for treating diastolic heart failure and/or relieving a symptom.

[Claim 7]

Use of 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, a salt thereof, a solvate